BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases
Shots:
- Fujifilm and Opsis to receive $30M up front and ~$40M as R&D and part of manufacturing funding for the development of 3 programs. The companies are eligible to receive development & commercial milestones along with royalties on a per-program basis
- BlueRock to get an option to license the 3 programs on a program-by-program basis and will be responsible for development & commercialization of the licensed products. Fujifilm and BlueRock will share manufacturing responsibilities and commercial supply- with Fujifilm responsible for clinical supply
- The companies will combine their expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases
Ref: Bayer | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com